跳至主要内容
临床试验/NCT06281691
NCT06281691
已完成
不适用

GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit

Jørgen Bjerggaard Jensen2 个研究点 分布在 2 个国家目标入组 127 人2023年12月28日

概览

阶段
不适用
干预措施
Xpert® Bladder Cancer Detection Test
疾病 / 适应症
Urinary Bladder Neoplasms
发起方
Jørgen Bjerggaard Jensen
入组人数
127
试验地点
2
主要终点
Accuracy of urinary marker (Xpert Bladder Cancer Detection Test) in patients undergoing cystoscopy for bladder cancer investigation
状态
已完成
最后更新
2个月前

概览

简要总结

The goal of this observational study is to evaluate whether a urinary biomarker (Xpert® Bladder Cancer Detection Test) can be used as a selection tool to decide which patients that should undergo cystoscopy in haematuria work-up or in other indications where bladder tumor is suspected. Hereby, the investigators will investigate in which patients where cystoscopy can be omitted, particularly in areas with limited access to urological service. With these more selected investigations, patients with bladder tumors will potentially be selected to earlier diagnosis compared to the current non-selected investigations with the inherent logistic and economical challenges. With this strategy, the investigators aim at improving the current poor prognosis for bladder cancer patients in Greenland.

详细描述

Methods: Citizens of Greenland above the age of 18 years referred for cystoscopy will be invited to participate in an observational study at the time of already planned cystoscopy. Hypothesis: The investigators hypothesize that the Xpert® Bladder Cancer Detection test can identify patients with a bladder tumor and serve as a future selection tool to support clinical decision whether to perform a cystoscopy or not - especially in areas with limited access to urological services. Perspectives: The investigators hope to improve the current poor prognosis for bladder cancer patients in Greenland with the early detection. If this is successful, it could change the way patients are examined for bladder cancer in Greenland, but in the long term also in Denmark and other countries. Thus, the study will be able to determine whether a simple urine examination should be introduced early in the current cancer program in order to reduce the number of patients who need to undergo a cystoscopy and who can avoid this and get an earlier clarification.

注册库
clinicaltrials.gov
开始日期
2023年12月28日
结束日期
2025年12月30日
最后更新
2个月前
研究类型
Observational
性别
All

研究者

发起方
Jørgen Bjerggaard Jensen
责任方
Sponsor Investigator
主要研究者

Jørgen Bjerggaard Jensen

Professor

Aarhus University Hospital

入排标准

入选标准

  • ≥18 years of age at the time of signing the Informed Consent Form with an indication for cystoscopy and planned for this already at study inclusion.
  • Ability to understand the Participant Information Sheet orally and in writing in either Danish or Greenlandic.
  • Signed Informed Consent Form.
  • Is, according to the Investigator's judgement, able to comply with the trial protocol.

排除标准

  • Patients not willing to participate.

研究组 & 干预措施

Greenlandic citizens aged 18 years and above, referred for cystoscopy

Patients who have been referred for a cystoscopy will be invited to participate in the study. During their cystoscopy appointment, they will be asked to provide a urine sample for the Xpert bladder cancer detection test.

干预措施: Xpert® Bladder Cancer Detection Test

结局指标

主要结局

Accuracy of urinary marker (Xpert Bladder Cancer Detection Test) in patients undergoing cystoscopy for bladder cancer investigation

时间窗: Baseline

To assess the reliability and precision of Xpert Bladder Cancer Detection test ability to correctly identify cases of bladder cancer in patients as part of the diagnostic investigation

研究点 (2)

Loading locations...

相似试验